Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 5 and last traded at GBX 5.42, with a volume of 45843 shares traded. The stock had previously closed at GBX 5.60.
Allergy Therapeutics Price Performance
The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The company’s fifty day moving average price is GBX 6.02 and its 200 day moving average price is GBX 8.61. The company has a market capitalization of £343.22 million, a P/E ratio of -5.59, a PEG ratio of -30.70 and a beta of 0.83.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
